Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo

被引:64
作者
Vingerhoeds, MH
Steerenberg, PA
Hendriks, JJGW
Dekker, LC
vanHoesel, QGCM
Crommelin, DJA
Storm, G
机构
[1] UNIV UTRECHT,UTRECHT INST PHARMACEUT SCI,DEPT PHARMACEUT,NL-3508 TB UTRECHT,NETHERLANDS
[2] NATL INST PUBL HLTH & ENVIRONM PROTECT,PATHOL LAB,NL-3720 BA BILTHOVEN,NETHERLANDS
[3] UNIV NIJMEGEN,FAC MED,DEPT MED ONCOL,NL-6500 HB NIJMEGEN,NETHERLANDS
关键词
immunoliposome; doxorubicin; targeted drug delivery; ovarian cancer; monoclonal antibody;
D O I
10.1038/bjc.1996.484
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This paper deals with the utility of immunoliposomes for the delivery of doxorubicin (DXR) to human ovarian carcinoma cells in vitro and in vivo. We aimed to investigate whether immunoliposome-mediated targeting of DXR to ovarian cancer cells translates in an enhanced anti-tumour effect compared with that of non-targeted DXR liposomes (lacking the specific antibody). Target cell binding and anti-tumour activity of DXR immunoliposomes were studied in vitro and in vivo (xenograft model of ovarian carcinoma). In vitro we observed that target cell binding and cell growth inhibition of DXR immunoliposomes is superior to that of non-targeted DXR-liposomes. However, in vivo, despite the efficient target cell binding and good antitumour response of DXR-immunoliposomes, no difference in anti-tumour effect, compared with non-targeted DXR-liposomes, could be determined. The results indicate that premature DXR leakage from immunoliposomes occurring before the actual target cell binding and subsequent DXR association with the tumour cells, explains why no significant differences in anti-tumour activity between DXR-immunoliposomes and non-targeted DXR-liposomes were observed in vivo.
引用
收藏
页码:1023 / 1029
页数:7
相关论文
共 30 条
[1]  
[Anonymous], 1993, J LIPOSOME RES, DOI DOI 10.3109/08982109309148213]
[2]  
BOERMAN O, 1990, ANTICANCER RES, V10, P1289
[3]  
DEEPE G, 1985, GYNECOL ONCOL, V20, P269
[4]   A PHASE-I/II STUDY OF INTRAPERITONEALLY ADMINISTERED DOXORUBICIN ENTRAPPED IN CARDIOLIPIN LIPOSOMES IN PATIENTS WITH OVARIAN-CANCER [J].
DELGADO, G ;
POTKUL, RK ;
TREAT, JA ;
LEWANDOWSKI, GS ;
BARTER, JF ;
FORST, D ;
RAHMAN, A .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1989, 160 (04) :812-819
[5]  
Fiske CH, 1925, J BIOL CHEM, V66, P375
[6]   USE OF ANIONIC LIPOSOMES FOR THE REDUCTION OF CHRONIC DOXORUBICIN-INDUCED CARDIOTOXICITY [J].
FORSSEN, EA ;
TOKES, ZA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (03) :1873-1877
[7]  
HAMILTON TC, 1984, CANCER RES, V44, P5286
[8]  
HAMILTON TC, 1983, CANCER RES, V43, P5379
[9]   TRANSMEMBRANE AMMONIUM-SULFATE GRADIENTS IN LIPOSOMES PRODUCE EFFICIENT AND STABLE ENTRAPMENT OF AMPHIPATHIC WEAK BASES [J].
HARAN, G ;
COHEN, R ;
BAR, LK ;
BARENHOLZ, Y .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1151 (02) :201-215
[10]  
MARKMAN M, 1991, SEMIN ONCOL, V18, P248